Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More [Yahoo! Finance]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Yahoo! Finance
clinical-stage biotechs like Disc Medicine, Inc . IRON and Verve Therapeutics VERV plunged on disappointing updates. Recap of the Week's Most Important Stories Updates From BMY Bristol Myers Squibb BMY announced that the European Commission (EC) has approved a label expansion of Reblozyl (luspatercept). The EC expanded the drug's label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (EU) member states. The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior efficacy compared to epoetin alfa in the study's primary endpoint of concurrent red blood cell transfusion independence and hemoglobin increase. Safety results were consistent with previous MDS studies and in line with expected symptoms in this patient population. Reblozyl is already indicated in the EU
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024PR Newswire
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsGlobeNewswire
- Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 2/7/24 - Beat
VNDA
Analyst Actions
- 2/9/24 - TheStreet
VNDA
Sec Filings
- 5/3/24 - Form 8-A12B/A
- 5/3/24 - Form 8-K
- 4/29/24 - Form ARS/A
- VNDA's page on the SEC website